title: Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis.
abstract: In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P<0.0005) and 2.4% greater at the femur (95%CI 0.8 to 3.9%, P<0.005) than the group not treated with bisphosphonates. Oral bisphosphonate therapy had a beneficial effect on BMD in adults with CF.
authors.affiliation: Department of Endocrinology, St Vincent's University Hospital, Dublin, Ireland. tomjcawood@eircom.net
authors.forename: T J
authors.initials: TJ
authors.lastname: Cawood
authors.forename: M J
authors.initials: MJ
authors.lastname: McKenna
authors.forename: C G
authors.initials: CG
authors.lastname: Gallagher
authors.forename: D
authors.initials: D
authors.lastname: Smith
authors.forename: Y C
authors.initials: YC
authors.lastname: Wen
authors.forename: J
authors.initials: J
authors.lastname: Gibney
authors.forename: J D
authors.initials: JD
authors.lastname: Dodd
authors.forename: D
authors.initials: D
authors.lastname: O'Shea
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015519:Bone Density / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003550:Cystic Fibrosis / Q000503:physiopathology*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates